A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. / Senkowski, Wojciech; Gall-Mas, Laura; Falco, Matías Marín; Li, Yilin; Lavikka, Kari; Kriegbaum, Mette C.; Oikkonen, Jaana; Bulanova, Daria; Pietras, Elin J.; Voßgröne, Karolin; Chen, Yan Jun; Erkan, Erdogan Pekcan; Dai, Jun; Lundgren, Anastasia; Grønning Høg, Mia Kristine; Larsen, Ida Marie; Lamminen, Tarja; Kaipio, Katja; Huvila, Jutta; Virtanen, Anni; Engelholm, Lars; Christiansen, Pernille; Santoni-Rugiu, Eric; Huhtinen, Kaisa; Carpén, Olli; Hynninen, Johanna; Hautaniemi, Sampsa; Vähärautio, Anna; Wennerberg, Krister.

In: Developmental Cell, Vol. 58, No. 12, 2023, p. 1106-1121.e7.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Senkowski, W, Gall-Mas, L, Falco, MM, Li, Y, Lavikka, K, Kriegbaum, MC, Oikkonen, J, Bulanova, D, Pietras, EJ, Voßgröne, K, Chen, YJ, Erkan, EP, Dai, J, Lundgren, A, Grønning Høg, MK, Larsen, IM, Lamminen, T, Kaipio, K, Huvila, J, Virtanen, A, Engelholm, L, Christiansen, P, Santoni-Rugiu, E, Huhtinen, K, Carpén, O, Hynninen, J, Hautaniemi, S, Vähärautio, A & Wennerberg, K 2023, 'A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids', Developmental Cell, vol. 58, no. 12, pp. 1106-1121.e7. https://doi.org/10.1016/j.devcel.2023.04.012

APA

Senkowski, W., Gall-Mas, L., Falco, M. M., Li, Y., Lavikka, K., Kriegbaum, M. C., Oikkonen, J., Bulanova, D., Pietras, E. J., Voßgröne, K., Chen, Y. J., Erkan, E. P., Dai, J., Lundgren, A., Grønning Høg, M. K., Larsen, I. M., Lamminen, T., Kaipio, K., Huvila, J., ... Wennerberg, K. (2023). A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Developmental Cell, 58(12), 1106-1121.e7. https://doi.org/10.1016/j.devcel.2023.04.012

Vancouver

Senkowski W, Gall-Mas L, Falco MM, Li Y, Lavikka K, Kriegbaum MC et al. A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. Developmental Cell. 2023;58(12):1106-1121.e7. https://doi.org/10.1016/j.devcel.2023.04.012

Author

Senkowski, Wojciech ; Gall-Mas, Laura ; Falco, Matías Marín ; Li, Yilin ; Lavikka, Kari ; Kriegbaum, Mette C. ; Oikkonen, Jaana ; Bulanova, Daria ; Pietras, Elin J. ; Voßgröne, Karolin ; Chen, Yan Jun ; Erkan, Erdogan Pekcan ; Dai, Jun ; Lundgren, Anastasia ; Grønning Høg, Mia Kristine ; Larsen, Ida Marie ; Lamminen, Tarja ; Kaipio, Katja ; Huvila, Jutta ; Virtanen, Anni ; Engelholm, Lars ; Christiansen, Pernille ; Santoni-Rugiu, Eric ; Huhtinen, Kaisa ; Carpén, Olli ; Hynninen, Johanna ; Hautaniemi, Sampsa ; Vähärautio, Anna ; Wennerberg, Krister. / A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids. In: Developmental Cell. 2023 ; Vol. 58, No. 12. pp. 1106-1121.e7.

Bibtex

@article{e182b848a62043c0b5caaf4651b15f48,
title = "A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids",
abstract = "The broad research use of organoids from high-grade serous ovarian cancer (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here, we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23%–38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic, and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in a culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data are explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.",
keywords = "3D cell culture, culture conditions, functional precision medicine, high-grade serous ovarian cancer, HPLM, organoid biobank, organoids, personalized medicine, scRNA-seq, tumor models",
author = "Wojciech Senkowski and Laura Gall-Mas and Falco, {Mat{\'i}as Mar{\'i}n} and Yilin Li and Kari Lavikka and Kriegbaum, {Mette C.} and Jaana Oikkonen and Daria Bulanova and Pietras, {Elin J.} and Karolin Vo{\ss}gr{\"o}ne and Chen, {Yan Jun} and Erkan, {Erdogan Pekcan} and Jun Dai and Anastasia Lundgren and {Gr{\o}nning H{\o}g}, {Mia Kristine} and Larsen, {Ida Marie} and Tarja Lamminen and Katja Kaipio and Jutta Huvila and Anni Virtanen and Lars Engelholm and Pernille Christiansen and Eric Santoni-Rugiu and Kaisa Huhtinen and Olli Carp{\'e}n and Johanna Hynninen and Sampsa Hautaniemi and Anna V{\"a}h{\"a}rautio and Krister Wennerberg",
note = "Publisher Copyright: {\textcopyright} 2023 The Author(s)",
year = "2023",
doi = "10.1016/j.devcel.2023.04.012",
language = "English",
volume = "58",
pages = "1106--1121.e7",
journal = "Developmental Cell",
issn = "1534-5807",
publisher = "Cell Press",
number = "12",

}

RIS

TY - JOUR

T1 - A platform for efficient establishment and drug-response profiling of high-grade serous ovarian cancer organoids

AU - Senkowski, Wojciech

AU - Gall-Mas, Laura

AU - Falco, Matías Marín

AU - Li, Yilin

AU - Lavikka, Kari

AU - Kriegbaum, Mette C.

AU - Oikkonen, Jaana

AU - Bulanova, Daria

AU - Pietras, Elin J.

AU - Voßgröne, Karolin

AU - Chen, Yan Jun

AU - Erkan, Erdogan Pekcan

AU - Dai, Jun

AU - Lundgren, Anastasia

AU - Grønning Høg, Mia Kristine

AU - Larsen, Ida Marie

AU - Lamminen, Tarja

AU - Kaipio, Katja

AU - Huvila, Jutta

AU - Virtanen, Anni

AU - Engelholm, Lars

AU - Christiansen, Pernille

AU - Santoni-Rugiu, Eric

AU - Huhtinen, Kaisa

AU - Carpén, Olli

AU - Hynninen, Johanna

AU - Hautaniemi, Sampsa

AU - Vähärautio, Anna

AU - Wennerberg, Krister

N1 - Publisher Copyright: © 2023 The Author(s)

PY - 2023

Y1 - 2023

N2 - The broad research use of organoids from high-grade serous ovarian cancer (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here, we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23%–38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic, and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in a culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data are explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.

AB - The broad research use of organoids from high-grade serous ovarian cancer (HGSC) has been hampered by low culture success rates and limited availability of fresh tumor material. Here, we describe a method for generation and long-term expansion of HGSC organoids with efficacy markedly improved over previous reports (53% vs. 23%–38%). We established organoids from cryopreserved material, demonstrating the feasibility of using viably biobanked tissue for HGSC organoid derivation. Genomic, histologic, and single-cell transcriptomic analyses revealed that organoids recapitulated genetic and phenotypic features of original tumors. Organoid drug responses correlated with clinical treatment outcomes, although in a culture conditions-dependent manner and only in organoids maintained in human plasma-like medium (HPLM). Organoids from consenting patients are available to the research community through a public biobank and organoid genomic data are explorable through an interactive online tool. Taken together, this resource facilitates the application of HGSC organoids in basic and translational ovarian cancer research.

KW - 3D cell culture, culture conditions

KW - functional precision medicine

KW - high-grade serous ovarian cancer

KW - HPLM

KW - organoid biobank

KW - organoids

KW - personalized medicine

KW - scRNA-seq

KW - tumor models

U2 - 10.1016/j.devcel.2023.04.012

DO - 10.1016/j.devcel.2023.04.012

M3 - Journal article

C2 - 37148882

AN - SCOPUS:85161580449

VL - 58

SP - 1106-1121.e7

JO - Developmental Cell

JF - Developmental Cell

SN - 1534-5807

IS - 12

ER -

ID: 360976198